173 related articles for article (PubMed ID: 18341668)
41. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
42. Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
van Hest RM; van Gelder T; Vulto AG; Mathot RA
Clin Pharmacokinet; 2005; 44(10):1083-96. PubMed ID: 16176120
[TBL] [Abstract][Full Text] [Related]
43. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
McCune JS; Baker KS; Blough DK; Gamis A; Bemer MJ; Kelton-Rehkopf MC; Winter L; Barrett JS
J Clin Pharmacol; 2013 Mar; 53(3):264-75. PubMed ID: 23444282
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation.
Krivoy N; Hoffer E; Tabak A; Elhasid R; Arush MW; Stein J; Yaniv I; Rowe JM
Pediatr Hematol Oncol; 2002; 19(1):31-7. PubMed ID: 11833485
[TBL] [Abstract][Full Text] [Related]
45. Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.
Sjöö F; El-Serafi I; Enestig J; Mattsson J; Liwing J; Hassan M
Clin Drug Investig; 2014 Jan; 34(1):43-52. PubMed ID: 24178237
[TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Paci A; Vassal G; Moshous D; Dalle JH; Bleyzac N; Neven B; Galambrun C; Kemmel V; Abdi ZD; Broutin S; Pétain A; Nguyen L
Ther Drug Monit; 2012 Apr; 34(2):198-208. PubMed ID: 22406655
[TBL] [Abstract][Full Text] [Related]
47. Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?
Buffery PJ; Allen KM; Chin PK; Moore GA; Barclay ML; Begg EJ
Ther Drug Monit; 2014 Feb; 36(1):86-92. PubMed ID: 24299921
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
Panetta JC; Kirstein MN; Gajjar A; Nair G; Fouladi M; Heideman RL; Wilkinson M; Stewart CF
Cancer Chemother Pharmacol; 2003 Dec; 52(6):435-41. PubMed ID: 13680158
[TBL] [Abstract][Full Text] [Related]
49. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
[TBL] [Abstract][Full Text] [Related]
50. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation.
Takama H; Tanaka H; Nakashima D; Ueda R; Takaue Y
Bone Marrow Transplant; 2006 Feb; 37(4):345-51. PubMed ID: 16400337
[TBL] [Abstract][Full Text] [Related]
51. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
[TBL] [Abstract][Full Text] [Related]
52. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
53. Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation.
Takamatsu Y; Sasaki N; Ogata K; Yukawa E; Jimi S; Hara S; Tamura K
Cancer Chemother Pharmacol; 2010 May; 65(6):1203-7. PubMed ID: 20169347
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
[TBL] [Abstract][Full Text] [Related]
55. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
[TBL] [Abstract][Full Text] [Related]
56. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
58. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
[TBL] [Abstract][Full Text] [Related]
59. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
Gaziev J; Isgrò A; Mozzi AF; Petain A; Nguyen L; Ialongo C; Dinallo V; Sodani P; Marziali M; Andreani M; Testi M; Paciaroni K; Gallucci C; De Angelis G; Alfieri C; Ribersani M; Lucarelli G
Pediatr Blood Cancer; 2015 Apr; 62(4):680-6. PubMed ID: 25557687
[TBL] [Abstract][Full Text] [Related]
60. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
